Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open indications, end of week, month and quarter

June 30, 2017 8:04am

With Friday marking the last trading day for the quarter, this is usually seen as a time when investors reposition their portfolios or take profits

Bring on the hot dogs as the market will bring the fireworks

Be safe out there … take precautions, keep your fingers away from any sell buttons or ticket writing

A critical indication ahead of “our” universe’s open!

Are you a subscriber? If not – you’re missing the realities of “our” universe!

I know what a company is supposed to look like, be like, and smell like to succeed!

Higher open expected

Dow futures are UP +0.21% and NASDAQ futures are UP +0.25%

U.S. stock index futures pointed to a slightly higher open on Friday, as investors looked to more data releases and moves in oil.

European markets were under pressure as major central banks suggested the era of cheap money may be coming to an end.

Asian markets closed lower despite China manufacturing activity beating expectations, as select tech shares around the region sold off.

Data docket: with personal income and outlays data due out at 8.30 a.m. ET, followed by Chicago PMI at 9.45 a.m. ET. Consumer sentiment is slated to come out at 10.00 a.m. ET. No major earnings or bond auctions are scheduled.

The cell therapy sector closed Thursday closed NEGATIVE, POSITIVE on Wednesday, NEGATIVE on Tuesday, and POSITIVE on Monday and last Friday.

The cell therapy sector’s record over the last 5 sessions (of 43 covered companies):

· Thursday closed NEGATIVE with 28 decliners, 13 advancers and 2 flats;

· Wednesday closed POSITIVE with 9 decliners, 31 advancers and 3 flats;

· Tuesday closed NEGATIVE with 32 decliners, 10 advancers and 1 flat;

· Monday closed POSITIVE with 15 decliners, 26 advancers and 2 flats;

· Last Friday closed POSITIVE with 14 decliners, 24 advancers and 5 flats;

Remembering Thursday’s closing bell newsletter, “volatility sweeps the sector wiping out strength and applying weakness “

As the first half of the year draws to a close, disappointment in the randomness of the cell therapy sector.

After alternating gains and losses every other day and thenthree (3) to four (4) consistent negative or positive closes - the first half stunk!

The health care indexes tried to show some life in 2017 but the ability to be consistent is missing.

The lows are low and the highs always peak quickly … thanks to volume,

The quarter is over and a downward path is ahead for spending.

What did I see on Thursday, U.S. stocks tumbled on Thursday, with the Dow on track for its biggest one-day drop in more than a month as the cell therapy sector sold-off? The Dow fell 164 points, or 0.8%, to 21,290, its biggest percentage decline since May 17. The S&P 500 index SPX, dropped 22 points, or 0.9%, to 2,418. The NASDAQ tumbled 111 points or 1.8% to 6,122 which is on track for its third straight session with a move of 1%, including a slump of 1.6% on Tuesday and Wednesday’s 1.4% rally—its biggest one-day rise since Nov. 7.

… The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market, traded near 11.44 … up +14.06% after Wednesday traded near 10.05 … DOWN -9.13%

You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?

Watch list:

The iShares Nasdaq Biotechnology (IBB) closed down -1.43% on Thursday, and indicated a POSITIVE +0.66% in Friday’s pre-market;
The SPDR S&P Biotech ETF (XBI) closed Thursday down -1.30%, and is NOT indicating In Friday’s pre-market;
The Health Care Select Sector SPDR ETF (XLV) closed down -0.93% Thursday, and is NOT indicating in Friday’s pre-open;
The iShares Russell 2000 (IWM) closed down -0.59% on Thursday, and indicating a POSITIVE +0.11% in Friday’s pre-opentake

Companies in my headlights:

…Your on you own today – I’m playing it safe and keeping my fingers off any buttons or tickets …..

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.